Cover Image
市場調查報告書

肝斑(黑皮病):全球臨床實驗檢討

Melasma (Chlosma) Global Clinical Trials Review, H1, 2016

出版商 GlobalData 商品編碼 296477
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
肝斑(黑皮病):全球臨床實驗檢討 Melasma (Chlosma) Global Clinical Trials Review, H1, 2016
出版日期: 2016年05月31日 內容資訊: 英文 57 Pages
簡介

本報告提供全球肝斑治療藥臨床實驗的相關調查,提供各地區,各階段,各狀態臨床實驗趨勢,彙整正在開發的藥物概要等,為您概述為以下內容。

目錄

簡介

各地區臨床實驗

  • 各國家臨床實驗及平均登記被實驗人數
    • 亞太地區的前幾名國家
    • 歐洲的前五名國家
    • 北美的前幾名國家
    • 中東·非洲的前幾名國家
    • 中南美的前幾名國家

G7各國臨床實驗

E7各國臨床實驗

各階段臨床實驗

各狀態臨床實驗

一定期間內募集的實驗對象

  • 贊助商各類型臨床實驗

主要的贊助商

肝斑臨床實驗參與計劃的主要企業

主要藥物

臨床實驗簡介

  • 主要企業
    • Galderma S.A.
    • Obagi Medical Products, Inc.
    • nPharmakon
    • maxingvest ag
    • LAL Clinica Pesquisa e Desenvolvimento Ltda
    • Khorakiwala Holdings and Investments Private Limited
    • Johnson & Johnson
    • Glenmark Pharmaceuticals Ltd.
    • Cipla Ltd.
    • CATALYSIS, S.L.
  • 大學·機關·醫院
    • Northwestern University
    • The University of Texas Southwestern Medical Center at Dallas
    • Universidad Autonoma de San Luis Potosi
    • Tehran University of Medical Sciences
    • Pontificia Universidad Catolica de Chile
    • Shahid Beheshti University
    • National University Hospital
    • Medical University of Vienna
    • Emory University
    • University of Miami

5個主要的臨床實驗簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3460CTIDB

GlobalData's clinical trial report, "Melasma (Chlosma) Global Clinical Trials Review, H1, 2016" provides an overview of Melasma (Chlosma) clinical trials scenario. This report provides top line data relating to the clinical trials on Melasma (Chlosma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Melasma (Chlosma) to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Melasma (Chlosma) to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Melasma (Chlosma) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials by Region, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Europe, Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016*
  • Proportion of Melasma (Chlosma) to Dermatology Clinical Trials, G7 Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Melasma (Chlosma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Melasma (Chlosma) to Dermatology Clinical Trials, E7 Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Melasma (Chlosma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Melasma (Chlosma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Europe, Top Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016*
  • Proportion of Melasma (Chlosma) to Dermatology Clinical Trials, G7 Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Melasma (Chlosma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Melasma (Chlosma) to Dermatology Clinical Trials, E7 Countries (%), 2016*
  • Melasma (Chlosma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Melasma (Chlosma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Melasma (Chlosma) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Melasma (Chlosma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Melasma (Chlosma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top